Literature DB >> 6858643

Retinopathy caused by treatment with tamoxifen in low dosage.

T Vinding, N V Nielsen.   

Abstract

In 17 patients treated with tamoxifen in a low dosage (30 mg daily) ophthalmological examination was performed. This revealed 2 cases with possible retinotoxic effect. A 64 year-old woman treated with tamoxifen for 9 months for metastatic breast cancer developed retinopathy with transitory visual impairment. The retinopathy was morphological characterised by multiple yellowish-white dots in the posterior pole, a parafoveal haemorrhage and accumulation of reticular pigment changes in the periphery of the retina. By retinal fluorescein angiography multiple non-fluorescent dots and hyperfluorescent areas were seen in the posterior pole. The retinal lesions remained unchanged except for the haemorrhage after discontinuation of the tamoxifen treatment. In another patient some of these changes were also found. The retinotoxic effect of tamoxifen has been reported previously with tamoxifen in high dosage (greater than or equal to 180 mg daily, minimal total dosage of 90 g) used for long periods, but never from this drug in low dosage (30 mg daily, minimal total dose 8.1 g-12.0 g).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6858643     DOI: 10.1111/j.1755-3768.1983.tb01393.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN: 0001-639X


  11 in total

1.  Tamoxifen retinopathy: a rare but serious complication.

Authors:  C R Bentley; G Davies; W A Aclimandos
Journal:  BMJ       Date:  1992-02-22

2.  Electrophysiological evaluation of visual pathways in paclitaxel-treated patients.

Authors:  V Scaioli; A Caraceni; C Martini; S Curzi; G Capri; G Luca
Journal:  J Neurooncol       Date:  2005-08-25       Impact factor: 4.130

Review 3.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 4.  Tamoxifen as adjuvant therapy in breast cancer. Current status.

Authors:  P N Plowman
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 5.  Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.

Authors:  V C Jordan
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

Review 6.  Clinically important ocular reactions to systemic drug therapy.

Authors:  I G Rennie
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

Review 7.  A risk-benefit assessment of tamoxifen therapy.

Authors:  W H Catherino; V C Jordan
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

Review 8.  Pulmonary and generalized lysosomal storage induced by amphiphilic drugs.

Authors:  Z Hruban
Journal:  Environ Health Perspect       Date:  1984-04       Impact factor: 9.031

9.  Imaging tamoxifen retinopathy using spectral-domain optical coherence tomography.

Authors:  Albert Caramoy; Paula Scholz; Sascha Fauser; Bernd Kirchhof
Journal:  GMS Ophthalmol Cases       Date:  2011-12-08

10.  Long-term comparisons of the efficacy, safety, and pregnancy outcomes of adjuvant tamoxifen plus ovarian function suppression in premenopausal Han and Zhuang Chinese patients with hormone receptor-positive early breast cancer.

Authors:  Shicong Tang; Qiong Zhang; Xianghui Tang; Dong Chen; Fan Zhang; Jianlun Liu; Wei Wei; Dequan Liu
Journal:  J Int Med Res       Date:  2018-10-25       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.